Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.

James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA.

BJU Int. 2010 Oct;106(7):966-73. doi: 10.1111/j.1464-410X.2010.09638.x.

PMID:
20840318
[PubMed - indexed for MEDLINE]
2.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
[PubMed - indexed for MEDLINE]
3.

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.

Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M.

Cancer. 2012 Nov 15;118(22):5709-18. doi: 10.1002/cncr.27674. Epub 2012 Jul 11.

PMID:
22786751
[PubMed - indexed for MEDLINE]
Free Article
4.

Zibotentan for the treatment of castrate-resistant prostate cancer.

Shepard DR, Dreicer R.

Expert Opin Investig Drugs. 2010 Jul;19(7):899-908. doi: 10.1517/13543784.2010.491822. Review.

PMID:
20497097
[PubMed - indexed for MEDLINE]
5.

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

Trump DL, Payne H, Miller K, de Bono JS, Stephenson J 3rd, Burris HA 3rd, Nathan F, Taboada M, Morris T, Hubner A.

Prostate. 2011 Sep;71(12):1264-75. doi: 10.1002/pros.21342. Epub 2011 Jan 26.

PMID:
21271613
[PubMed - indexed for MEDLINE]
6.

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.

Warren R, Liu G.

Expert Opin Investig Drugs. 2008 Aug;17(8):1237-45. doi: 10.1517/13543784.17.8.1237 . Review.

PMID:
18616419
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.

Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.

PMID:
23871417
[PubMed - indexed for MEDLINE]
Free Article
8.

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW.

J Clin Oncol. 2013 May 10;31(14):1740-7. doi: 10.1200/JCO.2012.46.4149. Epub 2013 Apr 8.

PMID:
23569308
[PubMed - indexed for MEDLINE]
9.

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Pili R, Häggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ.

J Clin Oncol. 2011 Oct 20;29(30):4022-8. doi: 10.1200/JCO.2011.35.6295. Epub 2011 Sep 19.

PMID:
21931019
[PubMed - indexed for MEDLINE]
10.

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R.

Invest New Drugs. 2011 Feb;29(1):118-25. doi: 10.1007/s10637-009-9318-5. Epub 2009 Sep 19.

PMID:
19763400
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.

Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):187-92. doi: 10.1038/pcan.2013.2. Epub 2013 Feb 5.

PMID:
23381694
[PubMed - indexed for MEDLINE]
12.

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ.

J Clin Oncol. 2008 May 20;26(15):2544-9. doi: 10.1200/JCO.2007.15.0367.

PMID:
18487572
[PubMed - indexed for MEDLINE]
13.

Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.

Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.

Urology. 2003 Jul;62(1):99-104.

PMID:
12837431
[PubMed - indexed for MEDLINE]
14.

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, Draper D, Venitz J, Jones E, Chen CC, Figg WD, Dahut WL.

BJU Int. 2009 Jun;103(12):1636-40. doi: 10.1111/j.1464-410X.2008.08327.x. Epub 2009 Jan 9.

PMID:
19154507
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).

Dawson N, Payne H, Battersby C, Taboada M, James N.

J Cancer Res Clin Oncol. 2010 Apr 14. [Epub ahead of print]

PMID:
20390429
[PubMed - as supplied by publisher]
16.

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.

Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB.

J Clin Oncol. 2003 Feb 15;21(4):679-89.

PMID:
12586806
[PubMed - indexed for MEDLINE]
17.

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS.

J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12.

PMID:
22583636
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Taneja SS.

J Urol. 2014 Mar;191(3):656. doi: 10.1016/j.juro.2013.11.085. Epub 2013 Nov 28. No abstract available.

PMID:
24522033
[PubMed - indexed for MEDLINE]
19.

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.

Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al.

J Urol. 1993 Jan;149(1):77-82; discussion 83.

PMID:
7678043
[PubMed - indexed for MEDLINE]
20.

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO.

J Clin Oncol. 2003 Dec 1;21(23):4277-84. Epub 2003 Oct 27.

PMID:
14581438
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk